Albert C. Koong, MD, PhD

home / authors / albert-c-koong-md-phd

Articles

Nonoperative Management of Rectal Cancer: A Modern Perspective

Yushen Qian, MD;Alexander L. Chin, MD, MBA;Diego A. S. Toesca, MD;Albert C. Koong, MD, PhD;Daniel T. Chang, MD

October 15th 2017

In this article, we provide a summary of nonoperative management of locally advanced rectal cancer in the modern era. Our focus is on technical details of tumor response and patient assessment after chemoradiotherapy, as well as a review of existing clinical data.

ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer

William Small, Jr, MD;John P. Hayes, MD;W. Warren Suh, MD, MPH;May Abdel-Wahab, MD, PhD;Ross A. Abrams, MD;Nilofer Azad, MD;Prajnan Das, MD, MS, MPH;Jadranka Dragovic, MD;Karyn A. Goodman, MD;Salma K. Jabbour, MD;William E. Jones III, MD;Andre A. Konski, MD, MBA, MA;Albert C. Koong, MD, PhD;Rachit Kumar, MD;Percy Lee, MD;Timothy M. Pawlik, MD;Joseph M. Herman, MD, MSc

July 15th 2016

These guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.

ACR Appropriateness Criteria® Rectal Cancer: Metastatic Disease at Presentation

Karyn A. Goodman, MD;Sarah A. Milgrom, MD;Joseph M. Herman, MD, MSc;May Abdel-Wahab, MD, PhD;Nilofer Azad, MD;A. William Blackstock, MD;Prajnan Das, MD;Theodore S. Hong, MD;Salma K. Jabbour, MD;William E. Jones III, MD;Andre A. Konski, MD, MBA, MA;Albert C. Koong, MD, PhD;Rachit Kumar, MD;Miguel Rodriguez-Bigas, MD;William Small, Jr, MD;Charles R. Thomas, Jr, MD;W. Warren Suh, MD

October 15th 2014

The management of rectal cancer in patients with metastatic disease at presentation is highly variable. Although chemoradiation is standard for patients with stage II/III rectal cancer, its role in the metastatic setting is controversial.